Recent Analysts’ Ratings Changes for Adlai Nortye (ANL)

Adlai Nortye (NASDAQ: ANL) has recently received a number of price target changes and ratings updates:

• 9/12/2026 – Adlai Nortye was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/10/2026 – Adlai Nortye is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $31.00 price target on the stock.
• 9/8/2026 – Adlai Nortye was given a new $49.00 price target by Loop Capital.
• 9/8/2026 – Adlai Nortye had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
• 8/22/2026 – Adlai Nortye was upgraded by Wall Street Zen from “hold” to “buy”.

Insider Transactions at Adlai Nortye

In other Adlai Nortye news, Director Ping Ji sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $16.63, for a total transaction of $83,150.00. Following the completion of the transaction, the director owned 131,667 shares in the company, valued at $2,189,622.21. The trade was a 3.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Xiaofeng Ye sold 5,667 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total value of $80,754.75. Following the transaction, the chief financial officer directly owned 147,757 shares in the company, valued at approximately $2,105,537.25. This represents a 3.69% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,667 shares of company stock worth $247,785 over the last three months.

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.

Adlai Nortye’s lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.